Stronger Care

Struggling with a rare mitochondrial disease that steals strength and breath?

The FDA just approved Kygevvi, the first-ever treatment for TK2 deficiency—offering a real survival boost for children who previously had almost no options.

Wondering which biotech just scored big for pushing ALS research forward?

MediciNova won a major innovation award for its drug MN-166, a promising therapy aiming to slow tough neurodegenerative diseases like ALS.

Wish Alzheimer’s treatments could actually reverse damage instead of just slowing it down?

Researchers used a new nanotech “shuttle” that cleared 50–60% of amyloid-beta in mouse brains—and even restored aging mice to youthful brain behavior.

From an ALS-targeting award winner to nanotech reversing Alzheimer’s in mice and the first drug for a rare mitochondrial disease, medicine is racing toward treatments that repair, restore, and rethink what’s possible.